Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium PresentationHOUSTON, Jan. 08, 2026 ...

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...

SPE/MPD MiniTec conference at MD&M West features medical polymer innovations, sustainability keynote, and device design ...

As Auckland continues to grow as a place for business, tourism and celebrations, the demand for adaptable spaces will only ...

A previous City of Lodi administration allegedly authorized staff to use government-issued credit cards to maximize any ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Sheinbaum discussed her recent call with Brazilian President Lula on Friday and responded to Trump's most recent threats ...

Q2 2026 Earnings Call Transcript January 8, 2026 Neogen Corporation beats earnings expectations. Reported EPS is $0.1, ...

Dolby Vision 2 delivers a significant leap in picture quality, bringing more lifelike color, better motion handling, and ...

GOTHENBURG, SE / ACCESS Newswire / January 6, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO ...

COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones.

The Opinion columnist M. Gessen examines how the president governs through spectacle, and the message his displays of force ...